# Masatoshi Makuuchi
**Masatoshi Makuuchi** (幕内雅敏) is a Japanese hepatobiliary surgeon, Emeritus Professor of the [University of Tokyo](https://www.edgepedia.org/university-of-tokyo), known for pioneering [liver resection](https://www.edgepedia.org/liver-resection) techniques and living-donor liver transplantation (LDLT). Born in 1946 in Tokyo, he grew up in a surgical family; according to a laudatio to Prof. Masatoshi Makuuchi, honorary member of ESOT, his father was a general surgeon.[1](https://www.frontierspartnerships.org/articles/10.1111/j.1432-2277.2008.00671.x/pdf) His research fields span hepatobiliary-pancreatic surgery, liver transplantation, and ultrasound medicine.[2](https://nrid.nii.ac.jp/nrid/1000060114641/)
| Fact | Detail |
|---|---|
| Born | 1946, Tokyo, Japan[1](https://www.frontierspartnerships.org/articles/10.1111/j.1432-2277.2008.00671.x/pdf) |
| Field | Hepatobiliary-pancreatic surgery, liver transplantation, ultrasound medicine[2](https://nrid.nii.ac.jp/nrid/1000060114641/) |
| M.D. |[3](https://www.sgo-iasgo.com/pdfs/cvs/Masatoshi_MAKUUCHI_CV.pdf) |
| Signature work | First successful LDLT in Japan (June 1990); first successful adult-to-adult LDLT worldwide (1993)[4](https://www.springermedicine.com/living-donor-liver-transplantation-looking-back-at-my-30-years-o/21257138) |
| Standard liver volume formula | SLV = 706.2 × body surface area + 2.4[4](https://www.springermedicine.com/living-donor-liver-transplantation-looking-back-at-my-30-years-o/21257138) |
| Current roles (Sept 2024) | President of Towa Hospital; Emeritus President, Japanese Red Cross Medical Center; Emeritus Professor, University of Tokyo[5](https://www.iasgo.com/2024/09/02/masatoshi-makuuchi-m-d-ph-d-facs-tokyo-japan-honorary-editor-in-chief/) • [3](https://www.sgo-iasgo.com/pdfs/cvs/Masatoshi_MAKUUCHI_CV.pdf) |
## Early life and training
Makuuchi studied medicine at the University of Tokyo Faculty of Medicine between 1967 and 1973, graduating in March 1973.[3](https://www.sgo-iasgo.com/pdfs/cvs/Masatoshi_MAKUUCHI_CV.pdf) • [1](https://www.frontierspartnerships.org/articles/10.1111/j.1432-2277.2008.00671.x/pdf) He was Resident Surgeon at Tokyo University Hospital from 1973 to 1974,[6](http://www.s466593873.onlinehome.fr/site%20institut/html/maitre/makuuchi_gb.htm)
## Career
He was appointed Head surgeon of the Hepatobiliary Division in 1988 and Chief Surgeon of the Operation Department in 1989.[5](https://www.iasgo.com/2024/09/02/masatoshi-makuuchi-m-d-ph-d-facs-tokyo-japan-honorary-editor-in-chief/)
## Representative work
His standard liver volume formula, used to size grafts and remnant livers for transplantation, is SLV = 706.2 × body surface area + 2.4.[4](https://www.springermedicine.com/living-donor-liver-transplantation-looking-back-at-my-30-years-o/21257138)
He was the first to use intraoperative ultrasonography during liver operations and pioneered anatomical hepatectomy and ultrasound-guided transhepatic [cholangiography](https://www.edgepedia.org/cholangiography) and drainage.[7](https://doi.org/10.3760/cma.j.issn.1673-9752.2018.01.013) His group developed systematic subsegmental resection using an ultrasound-guided indigoid dye injection method, balancing oncological curability against safety.[8](https://rcastoragev2.blob.core.windows.net/5cefff5753999b0bbe0906ff9f1451af/PMC7105847.pdf) According to *The History of Liver Surgery: Achievements over the Past 50 Years*, portal vein embolization was developed in the 1980s; the method consisted of artificial embolization of the right branch of the portal vein in order to cause atrophy of the resected side and enlargement of the remaining liver.[8](https://rcastoragev2.blob.core.windows.net/5cefff5753999b0bbe0906ff9f1451af/PMC7105847.pdf)
The Makuuchi criteria for hepatic resection, which include indocyanine green clearance, are widely used in Japan and other Asian countries to assess resectability in impaired livers.[8](https://rcastoragev2.blob.core.windows.net/5cefff5753999b0bbe0906ff9f1451af/PMC7105847.pdf) A Japanese nationwide survey found that meeting or exceeding these criteria was an independent factor for overall survival after hepatocellular carcinoma resection (hazard ratio 1.27; 95% CI, 1.18–1.36; p < 0.001).[9](https://doi.org/10.1111/hepr.13844)
## Contributions to liver surgery
In June 1990 his team performed the first successful living donor liver transplantation in Japan; the patient remained healthy 28 years later.[4](https://www.springermedicine.com/living-donor-liver-transplantation-looking-back-at-my-30-years-o/21257138) In 1993 his team performed the first successful adult-to-adult LDLT in the world; the recipient lived a normal life for 17 years until dying at age 70.[4](https://www.springermedicine.com/living-donor-liver-transplantation-looking-back-at-my-30-years-o/21257138)
Improvement in hepatocellular carcinoma surgery has been attributed to intraoperative ultrasound-guided procedures such as his segmentectomy, intermittent vascular occlusion, and precise indication criteria; operative mortality fell below 2% in the 1990s, with 5-year survival reaching nearly 50% in a recent Japanese nationwide survey.[10](https://doi.org/10.1159/000048280)
## Honors and recognition
He also received an award from the Princess Takamatsu Cancer Research Fund.[1](https://www.frontierspartnerships.org/articles/10.1111/j.1432-2277.2008.00671.x/pdf)
He was the first Asian honorary member of the European Society for Organ Transplantation, made honorary member in 2007.[1](https://www.frontierspartnerships.org/articles/10.1111/j.1432-2277.2008.00671.x/pdf)
## After retirement
From 2007 to 2017 he served as President of the Japanese Red Cross Medical Center, moving to Towa Hospital in April 2017, where he became President.[5](https://www.iasgo.com/2024/09/02/masatoshi-makuuchi-m-d-ph-d-facs-tokyo-japan-honorary-editor-in-chief/) As of a September 2024 announcement, he became President of Towa Hospital, Emeritus President of the Japanese Red Cross Medical Center, and Emeritus Professor of the University of Tokyo; the International Association of Surgeons, Gastroenterologists, and [Oncologists](https://www.edgepedia.org/oncologists) (IASGO) named him Honorary Editor-in-Chief in that announcement.[5](https://www.iasgo.com/2024/09/02/masatoshi-makuuchi-m-d-ph-d-facs-tokyo-japan-honorary-editor-in-chief/)
## References
1. Laudatio to Prof. Masatoshi Makuuchi, honorary member of ESOT – Prague 2007, https://www.frontierspartnerships.org/articles/10.1111/j.1432-2277.2008.00671.x/pdf
2. KAKEN, Researchers | MAKUUCHI Masatoshi (60114641), https://nrid.nii.ac.jp/nrid/1000060114641/
3. Curriculum Vitae Masatoshi MAKUUCHI, M.D., Ph.D., https://www.sgo-iasgo.com/pdfs/cvs/Masatoshi_MAKUUCHI_CV.pdf
4. Living donor liver transplantation: looking back at my 30 years of experience, https://www.springermedicine.com/living-donor-liver-transplantation-looking-back-at-my-30-years-o/21257138
5. Masatoshi MAKUUCHI, M.D., Ph.D., FACS Tokyo, Japan, Honorary Editor-in-Chief (IASGO), https://www.iasgo.com/2024/09/02/masatoshi-makuuchi-m-d-ph-d-facs-tokyo-japan-honorary-editor-in-chief/
6. MAKUUCHI Masatoshi / CURRICULUM VITAE, http://www.s466593873.onlinehome.fr/site%20institut/html/maitre/makuuchi_gb.htm
7. Academic contribution of Masatoshi Makuuchi: a master of hepatobiliary surgery, an example to learn from, https://doi.org/10.3760/cma.j.issn.1673-9752.2018.01.013
8. The history of liver surgery: Achievements over the past 50 years, https://rcastoragev2.blob.core.windows.net/5cefff5753999b0bbe0906ff9f1451af/PMC7105847.pdf
9. Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey, https://doi.org/10.1111/hepr.13844
10. Progress in Surgical Treatment of Hepatocellular Carcinoma, https://doi.org/10.1159/000048280
---
*Topic: Encyclopedia › Life and health › Life and health scientists › Medical and health researchers › Gastroenterology and hepatology researchers › Hepatologists*
*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026; Sep 30, 2026 · Edited: Sep 25, 2026; Sep 30, 2026; Oct 12, 2026; Oct 15, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license